» Articles » PMID: 22359474

Inhibition of Inducible Nitric Oxide Synthase Attenuates Monosodium Urate-induced Inflammation in Mice

Overview
Specialty Pharmacology
Date 2012 Feb 24
PMID 22359474
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The present study elucidated the effect of the selective inducible nitric oxide synthase (iNOS) inhibitor N(6)-(1-iminoethyl)-L-lysine (L-NIL) on monosodium urate (MSU) crystal-induced inflammation and edema in mice feet. L-NIL (5 or 10 mg/kg/day) was administered intraperitoneally 4 h before injection of MSU (4 mg) into the soles of mice hindlimb feet. Twenty-four hours after MSU injection, foot thickness was increased by 160% and L-NIL pretreatment reduced food pad swelling in a dose dependent manner. Pretreatment of 10 mg/kg/day L-NIL significantly suppressed the foot pad swelling by MSU. Plasma level of nitric oxide (NO) metabolites and gene expression and protein level of iNOS in feet were increased by MSU, which was suppressed by L-NIL pretreatment. Similar pattern of change was observed in nitrotyrosine level. MSU increased the gene expression of tumor necrosis factor (TNF)-α and interleukin (IL)-1β and L-NIL pretreatment suppressed MSU-induced cytokines expression. The mRNA levels of superoxide dismutase and glutathione peroxidase1 were increased by MSU and L-NIL pretreatment normalized the gene expression. Phosphorylation of extracellular signal-regulated kinase 1/2 and p38 was increased by MSU, which was suppressed by L-NIL pretreatment. The mRNA levels of iNOS, TNF-α, and IL-1β were increased by MSU in human dermal fibroblasts, C2C12 myoblasts, and human fetal osteoblasts in vitro, which was attenuated by L-NIL in a dose dependent manner. This study shows that L-NIL inhibits MSU-induced inflammation and edema in mice feet suggesting that iNOS might be involved in MSU-induced inflammation.

Citing Articles

Tissue accumulation of neutrophil extracellular traps mediates muscle hyperalgesia in a mouse model.

Suzuki K, Tsuchiya M, Yoshida S, Ogawa K, Chen W, Kanzaki M Sci Rep. 2022; 12(1):4136.

PMID: 35264677 PMC: 8907237. DOI: 10.1038/s41598-022-07916-8.


Integrated Strategy From , , to for Predicting Active Constituents and Exploring Molecular Mechanisms of Tongfengding Capsule for Treating Gout by Inhibiting Inflammatory Responses.

Yang W, Jiang X, Liu J, Qi D, Luo Z, Yu G Front Pharmacol. 2021; 12:759157.

PMID: 34912220 PMC: 8666879. DOI: 10.3389/fphar.2021.759157.


Involvement of inflammasome activation via elevation of uric acid level in nociception in a mouse model of muscle pain.

Yoshida S, Hagiwara Y, Tsuchiya M, Shinoda M, Koide M, Hatakeyama H Mol Pain. 2019; 15:1744806919858797.

PMID: 31161887 PMC: 6614954. DOI: 10.1177/1744806919858797.


[Ru(bpy)(NO)SO](PF), a Nitric Oxide Donating Ruthenium Complex, Reduces Gout Arthritis in Mice.

Rossaneis A, Longhi-Balbinot D, Bertozzi M, Fattori V, Segato-Vendrameto C, Badaro-Garcia S Front Pharmacol. 2019; 10:229.

PMID: 30914954 PMC: 6423075. DOI: 10.3389/fphar.2019.00229.


Cytokines are systemic effectors of lymphatic function in acute inflammation.

Aldrich M, Sevick-Muraca E Cytokine. 2013; 64(1):362-9.

PMID: 23764549 PMC: 3771384. DOI: 10.1016/j.cyto.2013.05.015.

References
1.
Grabowski P, Wright P, Van t Hof R, Helfrich M, Ohshima H, Ralston S . Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol. 1997; 36(6):651-5. DOI: 10.1093/rheumatology/36.6.651. View

2.
Cuzzocrea S, Chatterjee P, Mazzon E, McDonald M, Dugo L, Di Paola R . Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol. 2002; 453(1):119-29. DOI: 10.1016/s0014-2999(02)02338-5. View

3.
Kanellis J, Watanabe S, Li J, Kang D, Li P, Nakagawa T . Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003; 41(6):1287-93. DOI: 10.1161/01.HYP.0000072820.07472.3B. View

4.
Chicoine L, Tzeng E, Bryan R, Saenz S, Paffett M, Jones J . Intratracheal adenoviral-mediated delivery of iNOS decreases pulmonary vasoconstrictor responses in rats. J Appl Physiol (1985). 2004; 97(5):1814-22. DOI: 10.1152/japplphysiol.00193.2004. View

5.
Maki-Petaja K, Cheriyan J, Booth A, Hall F, Brown J, Wallace S . Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. Int J Cardiol. 2008; 129(3):399-405. DOI: 10.1016/j.ijcard.2008.02.011. View